BioCentury
ARTICLE | Financial News

Clover raises RMB62.8M in series A

December 15, 2017 8:42 PM UTC

On Dec. 14, Clover Biopharmaceuticals Inc. (Chengdu, China) raised RMB62.8 million ($9.5 million) in a series A round led by new investor Tianhe Life Sciences Venture Fund.

Clover is developing covalently trimerized fusion proteins using its Timer-Tag technology to target pathways that depend on the formation of trimers to initiate downstream signaling, such as TNF superfamily proteins and enveloped RNA virus antigens. ...

BCIQ Company Profiles

Clover Biopharmaceuticals Ltd.